All In Biotech

Drug Trial Radar · NCT07202663

Study of BB-025, Alone and After BB-031, in Healthy Volunteers

A Single Center, Two-part, Double-blind, Randomized, Placebo-controlled, Dose-escalation, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BB-025 or Placebo, Alone and Following a Single Dose of BB-031, in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Nov 5, 2025

Primary completion

Mar 18, 2026

Study completion Mar 18, 2026

Sponsor

Lead sponsor
Basking Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Oct 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this 2-part clinical trial is to learn about the safety and pharmacokinetics (PK) of a single dose of BB-025 when given on its own and after being given BB-031. Researchers will compare BB-025 to placebo (a look-alike substance that contains no drug) both on its own and after being given a single dose of BB-031 to assess the use of BB-025 as a reversal agent. In the first part of the study, participants will receive a single dose of BB-025 or placebo. They will be followed for 28 days to check if they have any symptoms. In the second part of the study, participants will receive a single dose of BB-031 and then be given either BB-025 or placebo. These participants will also be followed for 28 days to check if they have any symptoms.

Conditions

  • Pharmacodynamics
  • Pharmacokinetics
  • Healthy Volunteers

Interventions

  • BB-025Drug

    Reversal agent for BB-031

  • BB-031Drug

    RNA aptamer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety as assessed by adverse events (AEs)Time frame: From dosing of study drug to final visit (Day 28)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Scintia Clinical Research Ltd

    Randwick, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.